Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

@article{Zhanel1998InfluenceOH,
  title={Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.},
  author={George G Zhanel and Iain D. C. Kirkpatrick and Daryl J. Hoban and A. M. Kabani and James A Karlowsky},
  journal={Antimicrobial agents and chemotherapy},
  year={1998},
  volume={42 9},
  pages={
          2427-30
        }
}
The MICs and MBCs of 15 antibiotics for two strains of Staphylococcus aureus were determined in Mueller-Hinton broth (MHB) and 90% serum-10% MHB. Subsequent experiments established that highly protein-bound antibiotics (>/=80%), such as LY333328, demonstrated higher MICs and MBCs, less killing over an 8-h interval, and shorter postantibiotic effects in 90% serum-10% MHB than in MHB alone. Albumin was demonstrated to be almost solely responsible for changes in the aforementioned pharmacodynamic… CONTINUE READING

Figures, Tables, and Topics from this paper.

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Oritavancin: an investigational lipoglycopeptide antibiotic.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2013

Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.

  • Diagnostic microbiology and infectious disease
  • 2009
VIEW 3 EXCERPTS
CITES BACKGROUND

Impact of human serum albumin on oritavancin in vitro activity against enterococci.

  • Antimicrobial agents and chemotherapy
  • 2009
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES

Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium

Mercier, R.-C, H. H. Houlihan, M. J. Rybak
  • Antimicrob. Agents Chemother
  • 1997
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Appendix II: design and optimization of dosage regimens; pharmacokinetic data, p. 1707–1792

L. Z. Benet, S. Oie, J. B. Swartz
  • The pharmacological basis of therapeutics,
  • 1996
VIEW 1 EXCERPT

Methods for determining bactericidal activity of antimicrobial agents

K. Schmid
  • 1992

Protein binding and its significance in antibacterial therapy.

  • Infectious disease clinics of North America
  • 1989
VIEW 2 EXCERPTS